Inflammatory Bowel Disease
Expanded Profile

Novel serological markers for inflammatory bowel disease (IBD) **improve sensitivity and specificity** to aid in differential diagnosis and provide valuable prognostic information about disease behavior.

Clinical Application

- Five-marker IBD profile identifies and differentiates patients with ulcerative colitis (UC) and Crohn's disease (CD)
- Reported up to 97% specificity in differentiating UC from CD[1,2,3]
- Reported up to 70% sensitivity in identifying patients with UC[4,5]
- Reported up to 85.5% sensitivity in identifying patients with CD using multiple markers[6]
- 56.4% sensitivity in identifying CD patients who are anti-*Saccharomyces cerevisiae* antibody (ASCA) negative[6]
- Three prognostic levels for CD severity are provided, allowing for improved treatment decisions
- Test combination formulated to be appropriate and cost-effective for patients

Scientific Expertise

- Profile developed with only those markers that have been established in published research and are clinically relevant
- Crohn's disease risk levels and prognostic information validated in adults and children
- Interpretive reports include suggestive disease form and risk stratification for CD patients
- Expansive test options for IBD and related digestive disorders
- Expert MD and PhD consultation available

Superior Service

- Comprehensive laboratory services for the gastroenterology specialist
- Broad network of managed care health plans
- Flexible connectivity options for test ordering and reporting
- Patient service centers available nationwide
- Local account representation

Highly sensitive IBD profile for identifying patients with ulcerative colitis or Crohn's disease

LabCorp
Laboratory Corporation of America

Inflammatory Bowel Disease
Expanded Profile

Five-marker Profile	Ulcerative Colitis	Crohn's Disease	Crohn's with High Risk of Aggressive Disease	Crohn's with Very High Risk of Aggressive Disease
pANCA	Positive (+) Up to 70% sensitivity[4,5]	Negative (-)	Negative (-) or positive (+)	Negative (-) or positive (+)
gASCA IgG*	Negative (-)	Positive (+) 66.1% sensitivity[1]	Two positive (+) markers High risk[2]	Three or more positive (+) markers Very high risk[2]
ALCA IgG	Negative (-)	Positive (+) 85.5% sensitivity[6]		
ACCA IgA				
AMCA IgG				

Note: Risk levels for aggressive Crohn's disease behavior are based on published studies that included markers tested with prospective patient outcomes of disease complexity and/or surgery.[2,7,8]

*ASCA IgA was not included in the profile, as studies have shown there is little to no increase in clinical sensitivity or specificity for Crohn's disease when used in conjunction with gASCA IgG, ALCA IgG, ACCA IgA, and AMCA IgG.[9]

Inflamatory Bowel Disease Expanded Profile..... 162045**

Test Includes Antichitobioside carbohydrate antibodies (ACCA); antilaminaribioside carbohydrate antibodies (ALCA); antimannobioside carbohydrate antibodies (AMCA); anti-*Saccharomyces cerevisiae* antibodies (gASCA); atypical perinuclear antineutrophil cytoplasmic antibody (pANCA)

Specimen 1.0 mL serum in red-top or gel barrier tube

Methodology Enzyme immunoassay (EIA) for ACCA, ALCA, AMCA, gASCA; indirect fluorescent antibody (IFA) for atypical pANCA

**For the most current information regarding test options, including specimen requirements and CPT codes, please consult the online Test Menu at www.LabCorp.com.

Please contact your local account representative for more information or visit www.labcorp.com.

References

1. Dotan I, Fishman S, Dgani Y, et al. Antibodies against laminariboside and chitobioside are novel serologic markers in Crohn's disease. *Gastroenterology*. 2006;131:366-378.
2. Ferrante M, Liesbet H, Joossens M, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behavior. *Gut*. 2007;56:1394-1403.
3. Papp M, Altorjay I, Dotan N et al. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. *Am J Gastroenterol*. 2008;103:665-681.
4. Jaskowski TD, Litwin CM, Hill HR. Analysis of serum antibodies in patients suspected of having inflammatory bowel fisease. *Clin Vaccine Immunol*. 2006;13(6):655-660.
5. Quinton J-F, Sendid B, Reumaux D, et al. Anti-saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: Prevalence and diagnostic role. *Gut*. 1998;42:788-791
6. Malickova K, Lakatos PL, Bortlik M, Komarek V, Janatkova I, Lukas M. Anticarbohydrate antibodies as markers of inflammatory bowel disease in Central European cohort. *Eur J Gastroenterol Hepatol*. 2010;22(2):144-150.
7. Rieder F, Schleder S, Wolf A, et al. Association of the novel serologic anti-glycan antibodies anti-laminarin and anti-chitin with complicated Crohn's disease behavior. *Inflamm Bowel Dis*. 2010;16(2):263-274.
8. Rieder F, Schleder S, Wolf A, et al. Serum anti-glycan antibodies predict complicated Crohn's disease behavior: A cohort study. *Inflamm Bowel Dis*. 2010;16(8):1367-1375.
9. QUANTA LiteTM ASCA (S. cerevisiae) IgA [package insert]. San Diego, Calif: INOVA Diagnostics, Inc; 2005.

LabCorp
Laboratory Corporation of America

www.LabCorp.com